picibanil

Small molecule

UUniversity of Iowa

picibanil is one of 10 small molecule programs targeting Lymphatic Malformation. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphatic MalformationActive, not recruiting

Lymphatic MalformationPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Lymphatic Malformation

#DrugCompanyPhaseTrials

Blenoxane

Bristol-Myers Squibb

Phase 2

2 2

Piqray

Novartis

Phase 2

1 3

Viagra

VViatris Specialty LLC

Phase 2

2 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 5

Rapamune

PPrism Pharmaceuticals

Phase 2

1 6

Rapamycin

MMaastricht Radiation Oncology

Phase 2

1 7

TARA-002

PProtara Therapeutics

Phase 2

1 8

PTX-022

PPalvella Therapeutics, Inc.

Phase 2

1 9

Selenium

SSWOG Cancer Research Network

Phase 1

1 10

picibanil

UUniversity of Iowa

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphatic Malformation1 trial

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

Completed·UUniversity of Iowa·Phase 2/3·NCT00010452·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for picibanil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — picibanil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for picibanil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Iowa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Iowa

picibanil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphatic Malformation1 trial

References

Drug Info

Quick Facts

Related News